Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A long-acting FGF21 attenuates metabolic dysfunction-associated steatohepatitis-related fibrosis by modulating NR4A1-mediated Ly6C phenotypic switch in macrophages.

British journal of pharmacology - 1 Aug 2024

Ji Yue, Duan Yiliang, Li Yuanyuan, Lu Qingzhou, Liu Dingkang, Yang Yifan, Chang Ruilong, Tian Jing, Yao Wenbing, Yin Jun, Gao Xiangdong

Abstract excerpt

BACKGROUND AND PURPOSE: Because of the absence of effective therapies for metabolic dysfunction-associated steatohepatitis (MASH), there is a rising interest in fibroblast growth factor 21 (FGF21) analogues due to their potential anti-fibrotic activities in MASH treatment. PsTag-FGF21, a long-acting FGF21 analogue, has demonstrated promising therapeutic effects in several MASH mouse models. However, its efficacy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cells, Cultured
Share to Fatty Liver

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fibroblast Growth Factors

Share to Hepatic Stellate Cells

Share to Liver Cirrhosis

Share to Macrophages

Share to Mice, Inbred C57BL

Source

Identifiers

PMID: 38679486
DOI: 10.1111/bph.16378

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A long-acting FGF21 attenuates metabolic dysfunction-associated steatohepatitis-related fibrosis by modulating NR4A1-mediated Ly6C phenotypic switch in macrophages.PMID 38679486Read ↗

Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)Semantic proximity Read ↗

Fibroblast growth factor 21 is a hepatokine involved in MASLD progression.Semantic proximity Read ↗

Understanding Macrophage Complexity in Metabolic Dysfunction-associated Steatotic Liver Disease: Transitioning from the M1/M2 Paradigm to Spatial DynamicsSemantic proximity Read ↗

Understanding Macrophage Complexity in Metabolic Dysfunction-Associated Steatotic Liver Disease: Transitioning from the M1/M2 Paradigm to Spatial DynamicsSemantic proximity Read ↗

CXCR3+ LEF1low NK cells cause immunopathological hepatic damage in MASHSemantic proximity Read ↗

Characterization of the metabolic pathways and hepatic macrophage subsets in mouse models of MASHSemantic proximity Read ↗

PPARα-ERRα crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progressionSemantic proximity Read ↗

In vivo anti-FAP CAR T therapy reduces fibrosis and restores liver homeostasis in metabolic dysfunction-associated steatohepatitisSemantic proximity Read ↗

Notch signaling regulates macrophage-mediated inflammation in metabolic dysfunction-associated steatotic liver diseaseSemantic proximity Read ↗

TLR4 promotes liver fibrosis in metabolic dysfunction-associated steatohepatitis by a mechanism independent of hepatocytes and inflammatory cellsSemantic proximity Read ↗

Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling moduleSemantic proximity Read ↗

Combined Semaglutide and Exercise Ameliorate HFpEF-Associated MASH: Multi-Omics InsightsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.